GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » Cash And Cash Equivalents

4d pharma (4d pharma) Cash And Cash Equivalents : $20.61 Mil (As of Dec. 2021)


View and export this data going back to 2021. Start your Free Trial

What is 4d pharma Cash And Cash Equivalents?

4d pharma's quarterly cash and cash equivalents increased from Dec. 2020 ($11.79 Mil) to Jun. 2021 ($29.10 Mil) but then stayed the same from Jun. 2021 ($29.10 Mil) to Dec. 2021 ($20.61 Mil).

4d pharma's annual cash and cash equivalents increased from Dec. 2019 ($5.03 Mil) to Dec. 2020 ($11.79 Mil) and increased from Dec. 2020 ($11.79 Mil) to Dec. 2021 ($20.61 Mil).


4d pharma Cash And Cash Equivalents Historical Data

The historical data trend for 4d pharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Cash And Cash Equivalents Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash And Cash Equivalents
Get a 7-Day Free Trial 15.91 20.32 5.03 11.79 20.61

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.03 12.55 11.79 29.10 20.61

4d pharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


4d pharma  (OTCPK:LBPWQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


4d pharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of 4d pharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma (4d pharma) Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (4d pharma) Headlines

From GuruFocus

4D pharma to Participate in Jefferies London Healthcare Conference

By Business Wire Business Wire 11-11-2021

4D pharma to Present at the Microbiome Movement Drug Development Summit

By Business Wire Business Wire 06-22-2021

Update on Suspension of Trading

By Business Wire Business Wire 06-24-2022